ROSA Reality
ROSA Knee is the platform's commercial flagship, providing image-based and image-free workflows for total knee arthroplasty, with the robotic arm guiding bone resection through a constrained cutting envelope tied to the surgeon's preoperative plan. ROSA Hip extends the same architecture to anterior and posterior total hip arthroplasty workflows, where cup orientation and leg-length restoration are the precision-critical decisions. ROSA Shoulder addresses the emerging anatomic and reverse total shoulder market. ROSA Brain and ROSA Spine, inherited and extended through Zimmer Biomet's Medtech acquisition lineage, address stereotactic neurosurgical trajectory delivery and pedicle-screw placement respectively.
Across all five lines, the platform's defining property is that it is assistive rather than autonomous: the surgeon retains commit authority, and the robot enforces a planning envelope rather than executing the procedure. That assistive posture has been the regulatory and clinical foundation of the platform's success. It is also the property that the next generation of robotic-surgery regulation, reimbursement, and competitive pressure is going to push against, and the architectural substrate that defends, refines, and extends it is governed actuation.
Path Forward
Three forward pressures shape the trajectory. First, the FDA's evolving framework for AI-enabled medical devices, including Predetermined Change Control Plan authorization, contemplates surgical-robotic systems whose planning, registration, and execution components incorporate learned models that update post-market; an updatable surgical robot must be able to demonstrate that each commit-to-motion decision ran under an authorized actuation envelope, not merely that the device as a whole was cleared. Second, competitive dynamics across the orthopedic robotic category, where established platforms include Stryker Mako and Smith and Nephew CORI alongside emerging entrants, are trending toward workflows in which the surgeon supervises rather than continuously controls portions of the resection. Any move in that direction requires defensible mode escalation rather than a single fixed envelope.
Third, hospital and payer evidence requirements increasingly demand per-procedure outcome attribution. A platform that can bind each procedural step to a recorded actuation mode, a surgeon authorization, and a verification result produces evidence at the granularity that real-world outcome studies and value-based reimbursement programs are converging on.
A fourth forward pressure is medico-legal. Robotic-surgery liability allocation is shifting from device-level product liability to decision-level attribution as plaintiffs' experts gain access to richer intraoperative telemetry and as institutional review boards demand finer-grained incident analysis. A platform whose intraoperative substrate produces signed, per-stage actuation records distributes liability defensibly between surgeon, institution, and manufacturer. A platform whose substrate produces only aggregate device logs concentrates liability ambiguously and exposes the manufacturer to claims its architecture cannot rebut.
Architectural Fit
Graduated actuation modes decompose the procedure into a sequence of stages, registration, planning confirmation, exposure, resection, trial reduction, implant placement, closure, each admitted under an explicit mode whose envelope governs cutting depth, force, trajectory tolerance, and yield-on-resistance behavior. The mode selector reads the surgical plan, the intraoperative registration confidence, and a harm-minimization estimate, and admits the most autonomous mode whose envelope is provably sufficient for the stage. When intraoperative conditions degrade, soft-tissue tension exceeds plan, registration confidence drops, an unexpected anatomical variant is detected, the selector falls to a more constrained mode and surfaces the reason to the surgeon.
Reversibility evaluation is the architectural property that distinguishes surgical actuation from most other robotic domains: a bone cut is not reversible, an implant once seated cannot be removed without consequence, and a trajectory once delivered cannot be retracted without traversing the same tissue. Before committing to an irreversible step, the planner must show that the preceding stages closed cleanly, that the verification gate for the current stage admits the action, and that the surgeon-of-record authority covers the specific envelope being entered. Post-actuation verification then produces a signed record binding the stage, mode, authority, harm-minimization estimate, and observed outcome: feeding hospital quality registries, FDA post-market surveillance, and the platform's own learning loop on a substrate that supports PCCP-class authorization rather than impeding it.
Differentiation
Stryker's Mako platform, Smith and Nephew's CORI handheld system, and emerging entrants from Medtronic Mazor and Globus Excelsius compete on dimensions of haptic feedback, image-free workflow, footprint, and procedural breadth, but none have published an architectural primitive that binds each commit-to-motion decision to a graduated actuation mode, a surgeon-of-record authority, and a reversibility evaluation. Patient-specific instrumentation and navigation-only systems address the planning side of the problem but not the actuation side. Conventional surgical-robotic safety architectures rely on hard envelopes and watchdog circuits, which prevent gross excursion but do not produce per-step authorization records aligned with PCCP-class regulatory expectations.
The differentiation that matters commercially is that hospital procurement, surgeon training programs, and outcome registries are converging on per-procedure attribution. A platform that produces signed, per-stage actuation records aligned with quality-registry schemas wins contracts and registry partnerships that platforms relying on aggregate device-level documentation cannot.
Zimmer Position
Zimmer Biomet already operates the procedure-decomposition discipline, the surgeon-training infrastructure, and the regulatory engagement that a graduated-actuation architecture presupposes. What ROSA does not yet operate, in the public technical record, is an architectural primitive that binds each surgical step to an explicitly selected actuation mode, an authority of record, a reversibility evaluation, and a post-actuation verification record. Adopting graduated actuation modes with reversibility evaluation converts ROSA's existing assistive-by-design posture into an architectural property, defends it against competitive pressure toward less-supervised autonomy, and aligns it with the regulatory direction PCCP-class authorization is taking robotic surgery. The conversion is incremental: existing planning workflows, intraoperative tracking pipelines, and registry-reporting hooks become inputs to an explicit mode-selection substrate rather than implicit assumptions distributed across the platform.
How To Build It
A skilled implementer can construct the governed-actuation substrate from components already present in a modern surgical-robotic stack. The core element is a composite admissibility evaluator that ingests credentialed observations (registration confidence, tracking residuals, force and torque telemetry, plan conformance), an authority taxonomy (surgeon of record, delegated assistant, institutional policy scope), freshness bounds on each observation, and policy constraints, and returns one of a bounded set of dispositions: admit, gate, defer, solicit, reject, or escalate. Each proposed actuation is routed through this evaluator before any motion command reaches the arm.
The evaluator drives a graduated actuation mode selector. Embodiments range from a discrete mode ladder (fully constrained hold, envelope-limited assist, supervised autonomous cut sequence) to a continuous selector that produces an envelope parameterization over cutting depth, force ceiling, feed rate, trajectory tolerance, and yield-on-resistance behavior. The selector admits the most autonomous mode whose envelope the admissibility evaluation proves sufficient for the current stage, and falls to a more constrained mode when any input degrades, surfacing the governing reason.
A commitment-point evaluator classifies each proposed actuation by reversibility. A reversible motion (approach, hover, retractable registration touch) is admitted under a lighter gate; an irreversible commitment (bone cut, implant seating, trajectory delivery) requires that prior stages closed cleanly, that a freshness-bounded verification gate admits the step, and that the authority of record covers the specific envelope. Preemption budgets bound how much motion may proceed before re-evaluation, and graceful degradation defines the safe fallback when observations expire or authority lapses. Every disposition, mode transition, authority binding, and verification result is written to a lineage-recorded, signed provenance log, so the actuation is a governed, revocable, auditable act rather than a direct command. These primitives generalize across the ROSA Knee, Hip, Shoulder, Brain, and Spine workflows and, more broadly, across any actuation domain where physical commitments are partly irreversible.
Disclosure Scope
The mechanisms described here, composite admissibility evaluation, graduated actuation modes, reversibility-aware commitment-point evaluation, preemption budgets, authority-of-record binding, freshness bounds, graceful degradation, and lineage-recorded signed provenance, are disclosed in U.S. Provisional Application No. 64/049,409 and constitute the Governed Actuation inventive step of that filing. This publication is a dated public disclosure of that approach as of the filing date. References to Zimmer Biomet, ROSA, and the ROSA Knee, Hip, Shoulder, Brain, and Spine product lines, and to Stryker Mako, Smith and Nephew CORI, Medtronic Mazor, Globus Excelsius, and to FDA Predetermined Change Control Plan authorization, are external market and regulatory context provided for architectural comparison only. Those products and programs are the property of their respective owners, are described here from public information at the architecture level, and no capability, certification, clearance, contract, or incident is asserted beyond what is publicly reported. Nothing in that external context is a claim of the filing.
